BioMarin Pharma (NASDAQ: BMRN) announced data analysis for Kyndrisa demonstrating consistent evidence of efficacy in comparable patients across three randomized ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Management Comments

BioMarin (BMRN) PT Cut to $100 at Baird; Sees Drisapersen Approval 'Near-Zero'November 23, 2015 7:16 AM BioMarin (BMRN) PT Trimmed at Wedbush Following Briefing Docs; Sees Positive Read-Thru to SRPT, None to PTCTNovember 20, 2015 12:33 PM Despite Harsh BioMarin (BMRN) Briefing Docs, the Jury is Still Out - Leerink Partners November 20, 2015 10:21 AM BioMarin Pharma (BMRN) Briefing Docs 'Ugly' - Baird (SRPT)November 20, 2015 9:50 AM BioMarin Pharma (BMRN) Affirms Posting of Drisapersen NDA Briefing DocsNovember 20, 2015 8:11 AM BioMarin Announces Data Analysis Demonstrating Consistent Efficacy of Kyndrisa™ (drisapersen) in Comparable Patients Across Three Randomized StudiesNovember 20, 2015 8:11 AM FDA Posts Briefing Documents for Advisory Committee Meeting to Review Kyndrisa™ (drisapersen) for the Potential Treatment of Duchenne Muscular Dystrophy Amendable to Exon 51 SkippingNovember 20, 2015 8:10 AM FDA Posts Breifing Docs for BioMarin Pharma's (BMRN) DrisapersenNovember 20, 2015 7:59 AM BioMarin Pharma (BMRN) FDA briefing docs releasedNovember 20, 2015 7:59 AM